10.17.17
The New Jersey Innovation Institute, an NJIT Corp., and Rutgers University have formed the New Jersey Continuous Manufacturing Institute (NJCMI) that will serve as a center of excellence to advance new pharmaceutical manufacturing technologies.
The NJCMI will combine new technologies, infrastructure, facilities and technical expertise to support the development and continuous manufacture of pharmaceutical products. It will also provide training, education and workforce development.
The NJCMI facility features Process Development Pilot Plants for both solid dosage forms and biologics, as well as cGMP suites for production. It also provides individual Unit Operations labs for process optimization and control, modeling and automation. It also offers designated classrooms and training labs for collaborative learning experiences and workforce development.
Dr. Donald H. Sebastian, president of NJII said, “This partnership with Rutgers builds on over a decade of leading edge R&D, and deep faculty expertise that NJCMI can leverage to make available pilot-scale technologies that meet pharmaceutical industry demands for higher production volume, greater efficiency and reduced cost. I expect the center will be a strong magnet attracting all the links of the pharmaceutical value chain to make New Jersey a place of business.”
Dr. Christopher J. Molloy, senior vice president, Rutgers office of research & economic development stated, “NJCMI brings together a complete range of expertise and knowledge to develop innovative biopharmaceutical processing technologies. Our team is led by a core of professionals with more than 100 years of combined experience in biopharmaceutical manufacturing process development, biochemical and chemical engineering. Together, Rutgers and NJII, through the NJCMI, are meeting the challenges for cost effective approaches to the continuous production of both new and existing classes of pharmaceuticals.”
The NJCMI will combine new technologies, infrastructure, facilities and technical expertise to support the development and continuous manufacture of pharmaceutical products. It will also provide training, education and workforce development.
The NJCMI facility features Process Development Pilot Plants for both solid dosage forms and biologics, as well as cGMP suites for production. It also provides individual Unit Operations labs for process optimization and control, modeling and automation. It also offers designated classrooms and training labs for collaborative learning experiences and workforce development.
Dr. Donald H. Sebastian, president of NJII said, “This partnership with Rutgers builds on over a decade of leading edge R&D, and deep faculty expertise that NJCMI can leverage to make available pilot-scale technologies that meet pharmaceutical industry demands for higher production volume, greater efficiency and reduced cost. I expect the center will be a strong magnet attracting all the links of the pharmaceutical value chain to make New Jersey a place of business.”
Dr. Christopher J. Molloy, senior vice president, Rutgers office of research & economic development stated, “NJCMI brings together a complete range of expertise and knowledge to develop innovative biopharmaceutical processing technologies. Our team is led by a core of professionals with more than 100 years of combined experience in biopharmaceutical manufacturing process development, biochemical and chemical engineering. Together, Rutgers and NJII, through the NJCMI, are meeting the challenges for cost effective approaches to the continuous production of both new and existing classes of pharmaceuticals.”
